Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: Implications for cellular potency and selectivity over insulin receptor

Biochemical Pharmacology

Volumn 78, Issue 12, 2009, Pages 1438-1447

  Wood, Edgar R ^a   Shewchuk, Lisa ^a   Hassel, Anne ^a   Nichols, Jim ^a   Truesdale, Anne T ^a   Smith, Danielle ^a   Carter, H Luke ^a   Weaver, Kurt ^a   Barrett, George ^a   Leesnitzer, Tony ^a   Alvarez, Emilio ^a   Bardera, Ana Isabel ^a   Alamillo, Amelia ^a   Cantizani, Juan ^a   Martin, Julio ^a   Smith, Gary K ^a   Jensen, David E ^a   Xie, Hongbo ^a   Mook, Robert ^a   Kumar, Rakesh ^b   Kuntz, Kevin ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b Department of Oncology Biology ^*  (United States)

Author keywords

Cancer; Insulin like growth factor receptor; Kinase inhibitor; Receptor tyrosine kinase

Indexed keywords

INSULIN RECEPTOR; NVP AEW 541; PROTEIN KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ADIPOCYTES; ANIMALS; BINDING SITES; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349982602     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.07.022     Document Type: Article

References (47)

1. Yarden Y., and Ullrich A. Molecular analysis of signal transduction by growth factors. Biochemistry 27 (1988) 3113-3119
2. Favelyukis S., Till J.H., Hubbard S.R., and Miller W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Mol Biol 8 (2001) 1058-1063
3. Blakesley V.A., Scrimgeour A., Esposito D., and Le Roith D. Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling?. Cytokine Growth Factor Rev 7 (1996) 153-159
4. Manning B.D., and Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 129 (2007) 1261-1274
5. Peruzzi F., Prisco M., Dews M., Salomoni P., Grassilli E., Romano G., et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19 (1999) 7203-7215
6. Baserga R., Hongo A., Rubini M., Prisco M., and Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta (BBA)-Rev Cancer 1332 (1997) F105-F126
7. Lopez T., and Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1 (2002) 339-353
8. Miller B.S., and Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 65 (2005) 10123-10127 [Review] [57 refs]
9. Yuen J.S., and Macaulay V.M. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Therapeutic Target 12 (2008) 589-603
10. Dancey J., and Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2 (2003) 296-313
11. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23 (2005) 329-336
12. Mukherjee A., Dhadda A.S., Shehata M., and Chan S. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin Pharmacother 8 (2007) 2189-2204
13. Wheatley-Price P., and Shepherd F.A. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 20 (2008) 162-175
14. Bell I.M., Stirdivant S.M., Ahern J., Culberson J.C., Darke P.L., Dinsmore C.J., et al. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases. Biochemistry 44 (2005) 9430-9440
15. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., et al. In vivo antitumor activity of NVP-AEW541. A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 (2004) 231-239
16. Haluska P., Carboni J.M., Loegering D.A., Lee F.Y., Wittman M., Saulnier M.G., et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66 (2006) 362-371
17. Ji Q.S., Mulvihill M.J., Rosenfeld-Franklin M., Cooke A., Feng L., Mak G., et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 6 (2007) 2158-2167
18. Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5 (1986) 2503-2512
19. Emmitte K.A., Wilson B.J., Baum E.W., Emerson H.K., Kuntz K.W., Nailor K.E., et al. Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). Bioorg Med Chem Lett 19 (2009) 1004-1008
20. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., et al. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J Biol Chem 277 (2002) 1576-1585
21. McDonald O.B., Chen W.J., Ellis B., Hoffman C., Overton L., Rink M., et al. A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal Biochem 268 (1999) 318-329
22. Kaleko M., Rutter W.J., and Miller A.D. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10 (1990) 464-473
23. Debad J.D., Glezer E.N., Wohlstadter J.N., and Sigal G.B. Clinical and biological applications of ECL. In: Bard A.J. (Ed). Electrogenerated chemiluminescence (2004), Marcel Dekker, New York 43-78
24. Baer K., Al-Hasani H., Parvaresch S., Corona T., Rufer A., Nolle V., et al. Dimerization-induced activation of soluble insulin/IGF-1 receptor kinases: an alternative mechanism of activation. Biochemistry 40 (2001) 14268-14278
25. Wei L., Hubbard S.R., Hendrickson W.A., and Ellis L. Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain. J Biol Chem 270 (1995) 8122-8130
26. Park Y.W., Cummings R.T., Wu L., Zheng S., Cameron P.M., Woods A., et al. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. Anal Biochem 269 (1999) 94-104
27. Songyang Z., Kermit L., Eck M.J., Harrison S.C., Feldman R.A., Mohammadi M., et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373 (1995) 536-539
28. Braunwalder A.F., Yarwood D.R., Sills M.A., and Lipson K.E. Measurement of the protein tyrosine kinase activity of c-src using time-resolved fluorometry of europium chelates. Anal Biochem 238 (1996) 159-164
29. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter W.C. (Ed). Methods in enzymology: macromolecular crystallography part A vol. 276 (1997), Academic Press 307-326
30. Copeland R.A. Reversible inhibitors. Enzymes: a practical introduction to structure, mechanism and data analysis (2000), John Wiley and Sons, New York p. 266-304
31. Li W., and Miller W.T. Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase. J Biol Chem 281 (2006) 23785-23791
32. Rohlik Q.T., Adams D., Kull J., and Jacobs S. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun 149 (1987) 276-281
33. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16 (1997) 5572-5581
34. Hubbard S.R., Wei L., and Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372 (1994) 746-754
35. Munshi S., Hall D.L., Kornienko M., Darke P.L., and Kuo L.C. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 Å resolution. Acta Crystallogr Section D-Biol Crystallogr 59 (2003) 1725-1730
36. Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L., Stirdivant S.M., et al. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J Biol Chem 277 (2002) 38797-38802
37. Gualberto A., and Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene (2009)
38. Lindsay C.R., Chan E., Evans T.R., Campbell S., Bell P., Stephens A.W., et al. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 27 (2009) 2559
39. Rodon J., DeSantos V., Ferry R.J., and Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7 (2008) 2575-2588
40. Backes A.C., Zech B., Felber B., Klebl B., and Muller G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 3 (2008) 1427-1449
41. Noble M.E.M., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
42. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64 (2004) 6652-6659
43. Vajpai N., Strauss A., Fendrich G., Cowan-Jacob S.W., Manley P.W., Grzesiek S., et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283 (2008) 18292-18302
44. Gilmer T.M., Cable L., Alligood K., Rusnak D., Spehar G., Gallagher K.T., et al. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 68 (2008) 571-579
45. Gora-Tybor J., and Robak T. Targeted drugs in chronic myeloid leukemia. Curr Med Chem 15 (2008) 3036-3051
46. Gaudet E.A., Huang K.S., Zhang Y., Huang W., Mark D., and Sportsman J.R. A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J Biomol Screen 8 (2003) 164-175
47. Angell R.M., Atkinson F.L., Brown M.J., Chuang T.T., Christopher J.A., Cichy-Knight M., et al. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett 17 (2007) 1296-1301